February 26, 2021
NOT-TR-23-024 - Notice of Early Termination of NOT-TR-21-022, Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs.
PA-20-135 - Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)
NOT-TR-21-024 - Notice of Information: NCATS to Issue an Emergency Competitive Revision Sole Source Award in Support of ACTIV-6
National Center for Advancing Translational Sciences (NCATS)
The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts by performing high-priority clinical studies and trials to test therapeutics for the Coronavirus Disease 2019 (COVID-19).
NCATS is soliciting applications for Emergency Competitive Revisions to Existing NIH Awards (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients for clinical studies and trials in support of COVID-19 therapeutic interventions as follows:
NCATS expects to issue 1-8 awards for clinical studies and trials in support of COVID-19 therapeutic interventions.
Application and Submission Information
Applications in response to this NOSI must be submitted using the following target opportunity or subsequently reissued equivalents.
To be eligible, the parent Clinical and Translational Science Award (CTSA) Program award on which the revision application is based must be active when the application is submitted. The proposed project and budget periods must be within the currently approved project period for the existing parent award.
Eligibility for applications to PA-20-135 is limited to the UL1 and U24 activity codes.
When developing applications in response to this NOSI, all instructions in the SF424 (R&R) Application Guide and in the target funding opportunity announcement (PA-20-135) must be followed, with the following additions:
Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact the Grants Management Specialist on their active award to determine eligibility and the Program Officer on their active award to discuss the proposed project in the context of the parent award.
Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.
Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:
Please contact the Program Officer on your active award.